AI assistant
ARS Pharmaceuticals, Inc. — Director's Dealing 2025
Nov 15, 2025
32159_dirs_2025-11-14_7b2d0e17-af92-44cb-90ed-7dc9fe029764.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2025-11-12
Reporting Person: Chakma Justin (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-11-12 | Common Stock | M | 30000 | $0.84 | Acquired | 166380 | Direct |
| 2025-11-12 | Common Stock | S | 30000 | $8.9119 | Disposed | 136380 | Direct |
| 2025-11-12 | Common Stock | S | 136380 | $8.8634 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-11-12 | Stock Option (Right to Buy) | $0.84 | M | 30000 | Disposed | 2029-07-04 | Common Stock (30000) | Direct |
Footnotes
F1: The weighted average sale price for the transaction reported was $8.9119, and the range of prices was between $8.87 and $8.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F2: The weighted average sale price for the transaction reported was $8.8634, and the range of prices was between $8.62 and $9.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3: Immediately exercisable.